"VSports在线直播" Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype
- PMID: 28890642
- PMCID: "VSports在线直播" PMC5565129
Reslizumab (Cinqair): An Interleukin-5 Antagonist for Severe Asthma of the Eosinophilic Phenotype (VSports app下载)
Abstract
Reslizumab (Cinqair), an interleukin-5 antagonist for severe eosinophilic asthma VSports手机版. .
"VSports在线直播" Conflict of interest statement
Disclosures: The authors report no commercial or financial interests in regard to this article.
References
-
- Hamid Q, Tulic MK, Liu MC, et al. Inflammatory cells in asthma: mechanisms and implications for therapy. J Allergy Clin Immunol. 2003;111(1 suppl):S5–S12. - PubMed
-
- Centers for Disease Control and Prevention. Most recent asthma data. Jun 7, 2017. [Accessed July 18, 2017]. Available at: www.cdc.gov/asthma/most_recent_data.htm (V体育官网入口).
-
- National Heart, Lung, and Blood Institute. What is asthma? Aug 4, 2014. [Accessed October 4, 2016]. Available at: www.nhlbi.nih.gov/health/health-topics/topics/asthma.
-
- National Heart, Lung, and Blood Institute Expert Panel. The Expert Panel Report 3 (EPR–3): Guidelines for the Diagnosis and Management of Asthma. Bethesda, Maryland: National Heart, Lung, and Blood Institute; 2016. [Accessed October 4, 2016]. Available at: www.nhlbi.nih.gov/files/docs/guidelines/asthgdln.pdf.
-
- Cinqair (reslizumab) prescribing information. Frazer, Pennsylvania: Teva Respiratory LLC; 2016.
V体育官网入口 - LinkOut - more resources
Full Text Sources
VSports app下载 - Molecular Biology Databases